Edition:
United Kingdom

GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,572.00GBp
19 Nov 2018
Change (% chg)

10.00 (+0.64%)
Prev Close
1,562.00
Open
1,559.60
Day's High
1,583.40
Day's Low
1,558.60
Volume
5,135,552
Avg. Vol
7,779,282
52-wk High
1,634.48
52-wk Low
1,235.20

Select another date:

Wed, Oct 31 2018

Photo

GSK feels shingles vaccine boost, but shares slip on drugs mix

LONDON GlaxoSmithKline's third-quarter earnings were lifted by demand for its new shingles vaccine on Wednesday, but the British drugs firm's shares slipped despite an improved outlook as analysts focused on some drugs missing forecasts.

GSK feels shingles vaccine boost, but shares slip on drugs mix

LONDON GlaxoSmithKline's third-quarter earnings were lifted by demand for its new shingles vaccine on Wednesday, but the British drugs firm's shares slipped despite an improved outlook as analysts focussed on some drugs missing forecasts.

UPDATE 3-GSK feels shingles vaccine boost, but shares slip on drugs mix

* Shares reverse gains to trade down 2 pct (Adds further quotes on drug pipeline, updates shares)

GSK beats Q3 forecasts on strong Shingrix sales, nudges up guidance

LONDON, Oct 31 Pharmaceutical firm GlaxoSmithKline beat expectations with a 3 percent rise in third-quarter sales and a 10 percent rise in earnings per share on Wednesday thanks in part to strong demand for its new shingles vaccine Shingrix.

Long-lasting HIV injection is a step closer after second GSK study

LONDON A once-monthly injection to control HIV proved as effective as daily pills in a second study by GlaxoSmithKline, paving the way for a new regimen that could be simpler for some patients to be filed with regulators.

Long-lasting HIV injection is a step closer after second GSK study

LONDON, Oct 30 A once-monthly injection to control HIV proved as effective as daily pills in a second study by GlaxoSmithKline, paving the way for a new regimen that could be simpler for some patients to be filed with regulators.

BRIEF-Boston Pharmaceuticals says licenses five programmes from GSK

* BOSTON PHARMACEUTICALS SAYS HAS IN-LICENSED A PORTFOLIO OF FIVE EARLY DEVELOPMENT PROGRAMMES FROM GLAXOSMITHKLINE

GSK resumes some doctor payments, backtracking on blanket ban

LONDON GlaxoSmithKline, which five years ago stopped paying doctors for promoting its drugs, said on Tuesday it would allow such payments once again in limited circumstances.

GSK resumes some doctor payments, backtracking on blanket ban

LONDON GlaxoSmithKline , which five years ago stopped paying doctors for promoting its drugs, said on Tuesday it would allow such payments once again in limited circumstances.

GSK resumes some doctor payments, backtracking on blanket ban

LONDON, Oct 2 GlaxoSmithKline, which five years ago stopped paying doctors for promoting its drugs, said on Tuesday it would allow such payments once again in limited circumstances.

Select another date: